ADHD market set to decline due to patent expiries

4 June 2024

The attention-deficit/hyperactivity disorder (ADHD) market across the seven major markets (7MM) is forecast to decline at a negative compound annual growth rate (CAGR) of 0.9% from $11.9 billion in 2022 to $10.9 billion in 2032.

The downturn will be driven by patent expiries, high generic uptake in the largest ADHD market, namely the USS, and limited innovator entrants, according to pharma analytics company GlobalData.

GlobalData’s latest report “Attention Deficit Hyperactivity Disorder (ADHD): Market Opportunity Assessment and Forecast to 2032”, anticipates a decline in sales growth across all ADHD drug classes (stimulants: amphetamines, methamphetamines, methylphenidates, alpha-2a adrenergic agonists; and non-stimulant noradrenergic reuptake inhibitors). The amphetamine class is expected to see the greatest decline at a negative CAGR of 6.1% for the period of 2022-32.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK